Ask VialBase
Enforcement action · FDA, DOJ, HHS, state boards

FDA Crackdown on Peptide Vendors (2025-2026) — VialBase News

Last updated · June 13, 2026

The FDA Crackdown on Peptide Vendors (2025-2026)

The “FDA crackdown” is the sustained 2024-2026 wave of federal and state action that ended the grey-market and compounded-peptide boom. It is not a single rule or raid — it is the convergence of three forces: (1) drug-shortage resolution that switched off the legal basis for compounding GLP-1s, (2) the 503A/503B bulk-substance framework that keeps most research peptides off-limits to compounding, and (3) escalating enforcement — mass FDA warning letters, DOJ criminal prosecutions, and state board actions — that pushed vendors to shut down. This note is the canonical hub; each phase links to its dated detail note.

The crackdown is what closed Science-Bio (Jan 2026) and Peptide-Sciences (Mar 2026) and triggered the warning letters that named Prime-Sciences, Mile-High-Compounds, and Gram-Peptides. It is the same wave that produced the Amino-Asylum raid.

Important nuance for VialBase content: the crackdown targets vendors and marketing claims, not personal possession. Most research peptides remain legal to possess and to sell labeled “for research use only / not for human consumption” — but the FDA judges intended use by marketing context, not by the disclaimer, so the grey-market disclaimer is legal cover, not a safe harbor.

Two distinct regulatory tracks (don’t conflate them)

The crackdown runs on two parallel tracks that get muddled in vendor marketing:

  1. The GLP-1 track (semaglutide / tirzepatide / liraglutide). These are FDA-approved drugs. Compounding was only ever legal because of a declared shortage. When the shortage resolved, the legal basis evaporated. This track is essentially closed.
  2. The research-peptide track (BPC-157, TB-500, CJC-1295, etc.). These are unapproved drugs. They were never legally compoundable for human use once placed in Category 2, and they remain unapproved even as the FDA re-evaluates them in 2026.

See FDA-503A-Category-System for the framework underneath both tracks.

Timeline

For the full chronology see regulatory-timeline-2024-2026. Key inflection points:

2023-2024 — The framework tightens

Jan-Feb 2025 — Shortage resolution + end of the category pipeline

  • Jan 7, 2025: FDA finalizes its revised interim policy on compounding from bulk drug substances — no new substances enter the Category 1/2/3 pipeline; new nominations must complete full PCAC review first (Federal Register, 2025-01-07).
  • Feb 21, 2025: FDA issues a Declaratory Order finding the semaglutide shortage resolved, removing all presentations from the shortage list (Foley & Lardner; McDermott).
  • Feb 24, 2025: Outsourcing Facilities Association (OFA) sues FDA over the semaglutide determination — OFA v. FDA, 4:25-cv-00174 (N.D. Tex.) (Cardiovascular Business). See GLP1-Manufacturer-Litigation-2025.

Mar-May 2025 — Compounding discretion sunsets, litigation fails

  • Compounding enforcement-discretion deadlines (the sunset):
    • Tirzepatide: 503A ended Feb 18, 2025, 503B ended Mar 19, 2025 (NCPA).
    • Semaglutide: 503A ended Apr 22, 2025, 503B ended May 22, 2025 (Alston & Bird).
  • Apr 24, 2025: Court denies OFA’s preliminary injunction in the semaglutide case; the enforcement timelines hold (FDA compounder-policy statement, 4/28/2025 update). A parallel OFA challenge on tirzepatide was likewise denied. After these deadlines, neither tirzepatide nor semaglutide appears on the 503B bulks list or the shortage list — so compounding them from bulk is no longer lawful (FDA, same source).
  • Apr 2025: Eli Lilly sues Strive and Empower over compounded tirzepatide; FDA warning letter to Empower’s Texas facility. See GLP1-Manufacturer-Litigation-2025.

Jun-Oct 2025 — Enforcement escalates from letters to raids and indictments

  • Jun 2025: FDA/DOJ raid on Amino-Asylum, a high-volume research-peptide vendor — physical enforcement, not just paperwork. See Amino-Asylum-FDA-Raid-Jun-2025.
  • Sep 9, 2025: FDA/HHS announce a broad initiative against misleading direct-to-consumer pharma advertising (thousands of letters; ~100 cease-and-desist) — the policy umbrella for the peptide letters (STAT, 2025-09-19).
  • Sep 16, 2025: FDA publishes 55+ warning letters to online sellers of compounded GLP-1s — the largest single-day enforcement action against the compounding industry (Wilson Sonsini). Cited violations: “sameness” claims equating compounded product with the approved brand, and trademark misuse. See FDA-GLP1-Warning-Letters-Sep-2025.
  • 2024-2025 DOJ wave: Tailor Made Compounding pleads guilty (owner: probation + home detention + ~$1.79M forfeiture); All American Peptide operators and BioPeptide Labs charged. See DOJ-Peptide-Criminal-Prosecutions-2025.
  • 2025-2026 state actions: Ohio Board of Pharmacy consent orders; California AB-1887 disclosure law (effective Jan 1, 2025); Florida clinic-license suspensions. See State-Level-Peptide-Enforcement-2025-2026.

2026 — Vendor closures, more letters, and a partial thaw on research peptides

  • Jan 2026: Science-Bio shuts down — an early grey-market casualty. See Science-Bio-Shutdown-January-2026.
  • Feb 20, 2026: FDA sends 30 warning letters to telehealth firms over compounded-GLP-1 website claims (Pharmaceutical Commerce; Fierce Pharma). See FDA-Telehealth-GLP1-Warning-Letters-Mar-2026.
  • Feb 27, 2026: HHS signals a potential reclassification/loosening of restrictions on research peptides (FDA-Reclassification-Announcement-Feb-2026) — a proposed reversal, not a final rule, and it has not stopped enforcement.
  • Mar 2026: Peptide-Sciences (~$7M/mo) shuts down with no public warning letter — timing aligns with the crackdown. See Peptide-Sciences-Shutdown-March-2026.
  • Mar 31 / Apr 7, 2026: FDA warning letters to 7 peptide companies — including Prime-Sciences, Gram-Peptides, and Mile-High-Compounds — newly treating bacteriostatic water sold alongside peptides as drug distribution. See FDA-Warning-Letters-April-2026.
  • Mid-April 2026: FDA removes ~12 peptides from Category 2 (BPC-157, TB-500, Semax, Epitalon, MOTS-c, Melanotan II, GHK-Cu, KPV, DSIP, Dihexa, Selank, certain Ipamorelin salt forms) (Newtropin summary; secondary sources date this Apr 15 vs Apr 22, 2026 — treat as mid-April pending the Federal Register notice).
    • Critical caveat (do not overstate): removal from Category 2 is not authorization to compound. The peptides enter a transitional state; they must clear PCAC review and formal notice-and-comment rulemaking to land on the 503A bulks list before legal compounding resumes (Newtropin; FDA 503A bulks-list process page). “Not banned” ≠ “approved.”
  • May 1, 2026: FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list (“no clinical need”), comment window open to June 29, 2026 — a move to permanently close compounded GLP-1s (Federal Register, 2026-05-01; FDA press). Proposed, not final.
  • Jul 23-24, 2026: PCAC met at White Oak under docket FDA-2025-N-6895 and voted on seven peptides — BPC-157, KPV, TB-500 and MOTS-c on Jul 23; Emideltide (DSIP), Semax and Epitalon on Jul 24 (FDA advisory-committee calendar). FDA’s own review team recommended against all seven; every briefing document closes with the identical formula that “a balancing of the criteria weighs against [substance] being placed on that list.” The committee overrode FDA staff and recommended six for the 503A bulks list, rejecting only Emideltide (DSIP).
    • Do not overstate this either. The vote is advisory and non-binding. FDA has not adopted it; none of the six is on the 503A bulks list; none is FDA-approved; compounding them is not permitted. Any change arrives as a proposed rule in the Federal Register with its own comment period. As of this writing FDA has published no minutes, transcript, or vote summary.
    • Also worth noting: per the law firm that attended, the nominators had withdrawn all of these nominations before the meeting, and FDA elected to evaluate the substances on its own initiative given the public interest.

Current state (as of July 2026)

  • Compounded GLP-1s: effectively dead. Shortage resolved, discretion ended, OFA injunctions denied, and the FDA has proposed to bar them from the 503B list. The comment window closed June 29, 2026 with no final determination published.
  • Research peptides (BPC-157 et al.): still unapproved drugs. ~12 were lifted out of Category 2 in mid-April 2026 and most now sit in no interim category; none is on the 503A bulks list. PCAC recommended six of them on Jul 23-24, 2026 — against FDA’s own reviewers — but a recommendation is not a listing. The reclassification is a thaw, not a green light.
  • Enforcement posture: unchanged by the vote. Mass warning letters are routine (55+ in Sep 2025, 30 in Feb 2026, 7 in Apr 2026), the FDA is expanding theories of liability (e.g., bacteriostatic water as a drug), and DOJ criminal referrals are live. Enforcement and reclassification proceed on parallel, independent tracks — neither removal from Category 2 nor a favourable PCAC vote shields a vendor from current enforcement.

What it means

For vendors

  • Selling GLP-1 compounds is no longer defensible on shortage grounds. Expect letters → injunctions → seizures → criminal referral as the escalation ladder.
  • “Research use only / not for human consumption” disclaimers do not immunize you: the FDA applies the Intended Use Doctrine based on marketing context (dosing tips, before/after photos, human-use framing). See the disclaimer analysis in DOJ-Peptide-Criminal-Prosecutions-2025.
  • Even a clean operator can be hit on ancillary products — the Apr 2026 letters treated bacteriostatic water bundled with peptides as drug distribution (FDA-Warning-Letters-April-2026).
  • The largest vendors are exiting pre-emptively (Peptide-Sciences, Science-Bio) rather than litigate — supply is consolidating and narrowing.

For buyers / researchers

  • Access to compounded GLP-1s via telehealth has largely closed; remaining sources are grey-market and legally exposed.
  • Research-peptide supply is thinning and quality is uncertain — USADA’s chief science officer warns buyers “don’t even know what’s inside that bottle” (USADA).
  • The mid-2026 reclassification does not make BPC-157 a legal therapeutic; it remains an unapproved drug pending PCAC/rulemaking.

For VialBase content strategy

  • This is the central regulatory narrative for the affiliate/GEO site: it explains why vendors close, why “research use only” is the standard framing, and why compounding-vs-grey-market is the key buyer distinction. Tie vendor-status notes back here.
  • regulatory-status-refresh-2026-06 — compound-specific status table (June 2026); corrects the 12-peptide list and GHK-Cu status in this note’s April 2026 timeline entry
  • regulatory-timeline-2024-2026 — full chronology
  • FDA-503A-Category-System — the compounding framework (503A vs 503B, Categories 1/2/3)
  • FDA-Category-2-Designations-2023-2024 — the original peptide restrictions being enforced
  • FDA-Revised-Interim-Policy-Jan-2025 — end of the category-nomination pipeline
  • Semaglutide-Compounding-Shortage-Resolution — the GLP-1 shortage sunset
  • GLP1-Manufacturer-Litigation-2025 — Lilly/Novo + OFA litigation
  • FDA-GLP1-Warning-Letters-Sep-2025 — the 55+ letter wave
  • FDA-Telehealth-GLP1-Warning-Letters-Mar-2026 — the 30-letter telehealth wave
  • FDA-Warning-Letters-April-2026 — the 7-company peptide letters
  • Amino-Asylum-FDA-Raid-Jun-2025 — physical enforcement
  • DOJ-Peptide-Criminal-Prosecutions-2025 — criminal track
  • State-Level-Peptide-Enforcement-2025-2026 — state boards/AGs
  • FDA-Reclassification-Announcement-Feb-2026 — proposed reversal (not final)
  • Science-Bio-Shutdown-January-2026, Peptide-Sciences-Shutdown-March-2026 — vendor closures
  • EMA-Synthetic-Peptide-Guideline-2026, TGA-Australia-Import-Restrictions-2026 — international parallels

Sources

Source: FDA, DOJ, HHS, state boards →